<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03906253</url>
  </required_header>
  <id_info>
    <org_study_id>FLR</org_study_id>
    <nct_id>NCT03906253</nct_id>
  </id_info>
  <brief_title>Effectiveness of Fractionated Laser Resurfacing to Protect Geriatric Skin From Actinic Neoplasia</brief_title>
  <official_title>Effectiveness of Fractionated Laser Resurfacing to Protect Geriatric Skin From Actinic Neoplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jeffrey B. Travers, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wright State Physicians</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is following up on previous studies that have demonstrated that geriatric subjects&#xD;
      respond different to ultraviolet B (UVB) light than young subjects. The treatment of&#xD;
      geriatric skin with dermal rejuvenation therapies (dermabrasion, fractionated laser&#xD;
      resurfacing) restores the appropriate UVB response. Ongoing studies have tested the ability&#xD;
      of fractionated laser resurfacing (FLR) to assess how long this wounding effect lasts-and&#xD;
      have found that this appears to be a durable response which lasts for at least two years. The&#xD;
      findings that FLR protects geriatric skin at two years is the impetus for this study.&#xD;
&#xD;
      This study is an interventional study to assess if FLR treatment of one forearm of geriatic&#xD;
      subjects with multiple actinic keratosis will result in the short-term removal of actinic&#xD;
      keratosis, and the long-term decrease in levels of future actinic keratosis and other&#xD;
      non-melanoma skin cancers in comparison to the untreated arm.&#xD;
&#xD;
      Study length and visit: The first part of the study is completed in 1 day then there are&#xD;
      follow up visits at 90 days and every 6 months for 5 years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 10, 2018</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in the Number of Actinic Keratosis due to FLR treatment.</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Investigator will assess the number of actinic keratosis on both forearms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in the Number Non-Melanoma Skin Cancers due to FLR treatment.</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Investigator will assess the number of actinic keratosis on both forearms.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Actinic Keratoses</condition>
  <condition>Aging</condition>
  <condition>Non-Melanoma Skin Cancer</condition>
  <arm_group>
    <arm_group_label>Factionated Laser Resurfacing - Right Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Right forearm treatment of fractionated laser resurfacing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Factionated Laser Resurfacing - Left Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Left forearm treatment of fractionated laser resurfacing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Fractionated Laser Resurfacing</intervention_name>
    <description>A rejuvenating laser that makes tiny holes in the very superficial part of the skin.</description>
    <arm_group_label>Factionated Laser Resurfacing - Left Arm</arm_group_label>
    <arm_group_label>Factionated Laser Resurfacing - Right Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with Actinic Keratosis within the past 6 months&#xD;
&#xD;
          -  At least 60 years of age, or older&#xD;
&#xD;
          -  Ability to comprehend procedures and risks versus benefits&#xD;
&#xD;
          -  Able to provide Informed Consent&#xD;
&#xD;
          -  Fair Skin (Fitzpatrick Type I or II)&#xD;
&#xD;
          -  Possess both Right and Left Forearms&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled Diabetes Mellitus&#xD;
&#xD;
          -  Not able to comprehend procedures or risks versus benefits&#xD;
&#xD;
          -  Pregnant or nursing&#xD;
&#xD;
          -  Large tattoos on forearms&#xD;
&#xD;
          -  History of abnormal healing or scarring (i.e., keloids)&#xD;
&#xD;
          -  Any disease that gets worse while in the sun&#xD;
&#xD;
          -  Use of topical or oral anti-inflammatory medication or steroids&#xD;
&#xD;
          -  Allergy to lidocaine&#xD;
&#xD;
          -  Current use of photosensitizing medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey B Travers, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wright State Physicians</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dayton VA Medical Center</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45428</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 4, 2019</study_first_submitted>
  <study_first_submitted_qc>April 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2019</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Wright State Physicians</investigator_affiliation>
    <investigator_full_name>Jeffrey B. Travers, MD, PhD</investigator_full_name>
    <investigator_title>Chair of Department of Pharmacology and Toxicology and Professor of Dermatology for Boonshoft School of Medicine at Wright State University</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis, Actinic</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
    <mesh_term>Keratosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

